TMDX Earnings Prediction
The chart below shows how TMDX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TMDX sees a +1.62% change in stock price 10 days leading up to the earnings, and a +12.85% change 10 days following the report. On the earnings day itself, the stock moves by -1.91%. This data can give you a slight idea of what to expect for the next quarter's release.
TMDX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
108.76M
63.72%
-4.85%
Gross Margin
55.85%
-8.76%
-7.70%
Operating Margin
3.61%
173.48%
-67.00%
Net Margin
3.88%
110.14%
-63.64%
EPS
0.12
115.38%
-65.71%
No Data Available
TMDX Earnings Analysis
TransMedics Group, Inc. Common Stock Corporation (TMDX.O) Earnings Conference Call
Positive
Q3 Revenue Surge: Total revenue for Q3 was $108.8 million, representing 64% growth from Q3 2023, driven by 76% year-over-year sales growth in the U.S.
Logistics Service Revenue Growth: TransMedics logistics service revenue for Q3 was $20.1 million, up from $2.1 million in Q3 2023 and up from $19.1 million in Q2 of 2024, an approximate 5% increase sequentially from Q2.
Gross Margin Decline: Our overall gross margins for Q3 was 56%, down from 61% in Q2 2024, reflecting the higher service component of our business.
Operating Profit Improvement: We delivered a GAAP operating profit of $3.9 million in Q3, representing 4% of total revenue, compared to an operating loss of $28.3 million in Q3 of 2023.
Net Income Improvement: Net income was $4.2 million, a significant improvement compared to a net loss of $25.4 million in Q3 of 2023.
Negative
Q3 Revenue Decline: Total revenue for Q3 was $108.8 million, representing a 5% sequential decline from last quarter.
Gross Margin Decline: Overall gross margins for Q3 was 56%, down from 61% in Q3 of 2023.
Revenue Decline Analysis: We saw a 5% decline in total revenue from Q2 2024.
Sales Decline Analysis: U.S. sales declined 3% sequentially and OUS sales declined 45% sequentially.
Cash Position Decline: Our overall cash at the end of the quarter was $330.1 million, a decrease of $32.7 million from June 30th, 2024.
TMDX FAQs
How does TMDX typically perform around its earnings report dates?
Is TransMedics Group, Inc. (TMDX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TMDX Earning Call Sentiment
TransMedics Group, Inc. (TMDX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
TMDX.O
5.82%Positive
The earnings call reveals a mix of positive and negative indicators. Strong revenue growth in the US and improved profitability are offset by significant international revenue declines and a decrease in gross margins. The Q&A session highlights uncertainties about future performance, and there's no shareholder return plan. Despite increased guidance, concerns about operational challenges and unclear management responses temper optimism. Given the market cap, the stock is likely to remain neutral over the next two weeks, with a possible slight positive tilt due to increased guidance.
